Old Mission Investment Co LLC Makes New Investment in Abbott Laboratories $ABT

Old Mission Investment Co LLC purchased a new stake in Abbott Laboratories (NYSE:ABT) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 18,548 shares of the healthcare product maker’s stock, valued at approximately $1,683,000.

Several other institutional investors and hedge funds also recently modified their holdings of ABT. J. Stern & Co. LLP raised its position in Abbott Laboratories by 12,439.6% in the 4th quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. Norges Bank bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $2,938,892,000. Bank of America Corp DE acquired a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $1,603,607,000. Legal & General Group Plc acquired a new position in Abbott Laboratories during the second quarter worth $1,082,524,000. Finally, Flossbach Von Storch SE bought a new position in Abbott Laboratories in the second quarter valued at $902,938,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Down 0.0%

ABT opened at $108.29 on Monday. The stock’s fifty day simple moving average is $104.43 and its 200 day simple moving average is $100.03. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The stock has a market cap of $187.38 billion, a PE ratio of 35.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.59. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the business posted $1.26 earnings per share. The company’s revenue for the quarter was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. As a group, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s payout ratio is presently 81.55%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ABT shares. Bank of America cut their price target on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wells Fargo & Company lifted their target price on Abbott Laboratories from $109.00 to $112.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. Royal Bank Of Canada reiterated an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. TD Cowen increased their price target on Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, August 25th. Finally, Wolfe Research upgraded Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research note on Thursday, August 13th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $119.50.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.